Eli Lilly and Company (NYSE:LLY) Holdings Cut by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,699 shares of the company’s stock after selling 328 shares during the period. Eli Lilly and Company makes up approximately 2.2% of Roman Butler Fullerton & Co.’s holdings, making the stock its 7th largest holding. Roman Butler Fullerton & Co.’s holdings in Eli Lilly and Company were worth $7,839,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of LLY. AMF Tjanstepension AB boosted its position in Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after acquiring an additional 176,552 shares in the last quarter. Values Added Financial LLC boosted its position in Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after acquiring an additional 17 shares in the last quarter. RFG Advisory LLC boosted its position in Eli Lilly and Company by 7.6% during the 3rd quarter. RFG Advisory LLC now owns 9,006 shares of the company’s stock valued at $7,979,000 after acquiring an additional 635 shares in the last quarter. Madrona Financial Services LLC boosted its position in shares of Eli Lilly and Company by 12.4% in the 3rd quarter. Madrona Financial Services LLC now owns 282 shares of the company’s stock worth $250,000 after purchasing an additional 31 shares in the last quarter. Finally, CHB Investment Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $2,764,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $844.82 on Friday. The firm has a market cap of $802.01 billion, a PE ratio of 72.15, a P/E/G ratio of 1.87 and a beta of 0.42. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a fifty day simple moving average of $794.44 and a two-hundred day simple moving average of $844.60. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. On average, equities analysts anticipate that Eli Lilly and Company will post 23.33 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.71%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is 44.41%.

Eli Lilly and Company announced that its board has approved a stock repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. Wolfe Research began coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.